PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Investigators conducted a multicenter, open-label, Phase II, single-arm study of pembrolizumab in patients with DIPSS intermediate 2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib.